Compare Nuvalent Inc (NUVL) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Okta, Inc. — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Okta, Inc. trades at $141.22 (market cap $25.79B). The key difference: Okta, Inc. is far larger — about 2.6× Nuvalent Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Okta, Inc. nearer its low. Which is the better fit depends on your goals.
| NUVL | OKTA | |
|---|---|---|
Market Cap | $9.81B | $25.79B |
Sector | Technology | Technology |
52-Week High | $123.96 | $154.62 |
52-Week Low | $72.16 | $62.93 |
Enterprise Value | $8.52B | $23.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKTA trades at $141.63, down 5.17% in the last session amid broader market volatility. The stock shows strong fundamental improvement with revenue growing to $2.61B in 2025 and achieving positive net income of $28M after years of losses. Technical indicators suggest a bullish trend with strong moving average signals, while oscillators remain neutral. Recent analyst coverage remains overwhelmingly positive with 37 buy ratings versus 2 sell ratings.
The outlook remains constructive given OKTA's position in the growing cybersecurity sector and improving profitability. Key risks include high valuation multiples (P/E of 107.54) and competitive pressures. The consensus price target of $127.96 suggests potential downside from current levels, though the high target of $175.00 indicates significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
